多阶段对齐和融合为多模式多类阿尔茨海默氏病诊断的多阶段对齐和融合
Shuo Huang1,2, Lujia Zhong1,3, Yonggang Shi1,2,3
1Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA 90033, USA.
概括
这项研究引入了用于早期阿尔茨海默病 (AD) 诊断的新AI框架,集成MRI,PET和认知得分,以准确地分类患有轻度认知障碍 (MCI) 和AD的个人. 这种新的方法实现了73.21%的准确性,超过了现有方法.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 生物标志物发现发现
背景情况:
- 早期诊断阿尔茨海默病 (AD) 对于有效治疗至关重要,但由于重叠的生物标志物分布,区分认知正常 (CN),轻度认知障碍 (MCI) 和AD患者具有挑战性.
- 当前的诊断方法与来自不同来源的数据的复杂性和异质性作斗争,限制了分类性能.
研究的目的:
- 开发一种新的多模式框架,用于对AD,MCI和CN的准确多类诊断.
- 整合多种数据类型,包括T1加权MRI,tau PET,扩散MRI衍生纤维定向分布 (FOD) 和蒙特利尔认知评估 (MoCA) 评分.
- 通过先进的特征提取和数据整合技术,通过解决疾病组之间的模糊性来提高分类性能.
主要方法:
- 开发了一个新的Swin-FOD模型,从FOD数据中提取顺序平衡的特征.
- 使用对比学习来调整从MRI和PET模式中提取的特征.
- 使用 Tabular Prior-data Fitted In-context Learning (TabPFN) 的上下文学习方法处理了对齐的多模式特征和MoCA分数,消除了微调的需要.
主要成果:
- 拟议的多模式框架在阿尔茨海默病神经成像倡议 (ADNI) 数据集 (n = 1147) 上实现了73.21%的诊断准确率.
- 该模型显著超过了十个比较模型,证明了优越的分类性能.
- 进行了沙普利分析,以定量评估每个单个模式对诊断准确性的贡献.
结论:
- 开发的多模式框架为准确和早期诊断阿尔茨海默病提供了一个有希望的方法.
- 整合不同的数据源,如MRI,PET,dMRI衍生的FOD和认知得分,可以有效地克服个别生物标志物的局限性.
- 新的特征提取和数据集成方法,特别是Swin-FOD模型和TabPFN,显示出在推进人工智能驱动的神经退行性疾病诊断方面具有重大潜力.
相关概念视频
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


